非小细胞肺癌患者中HER2基因突变的临床特征及预后
Clinical features and prognosis of non-small cell lung cancer harboring HER2 mutations
摘要
Abstract
Objective: To investigate clinical features and prognosis of non-small cell lung cancer (NSCLC) harboring HER2 mutations. Methods: We retrospectively reviewed clinical features from 15 patients with NSCLC harboring HER2 mutations, and the survival rate was calculated by Kaplan-Meier method and log-rank test was used to compare the survival rates. Results: HER2 gene mutation rate was 1.92% (15/781) in non-small cell lung cancer, mutation rate of female was much higher than male (3.76% vs 1.23%, P=0.022), and current-smoker was much higher than no-smoker (3.17% vs 0.74%, P=0.027), the median overall survival time was 42.6 months, including 12 cases compound mutation, the median overall survival time for 42.6 months, 3 cases simple mutation, the median overall survival time for 40.3 months, but both no statistical difference (P=0.43), with EGFR mutations in 8 cases,the median overall survival time for 50.6 months, and without EGFR mutations in 7 cases, the median overall survival time for 42.6 months (P=0.19), with TP53 mutations in 9 cases, the median overall survival time for 40.4 months, and without TP53 mutations in 6 cases, the median overall survival time for 46.7 months (P=0.39),with SMARCA4 mutations in 2 cases, the median overall survival time for 50.6 months, and without SMARCA4 mutations in 13 cases, the median overall survival time for 42.6 months (P=0.33), with MTOR mutations in 2 cases, the median overall survival time for 44.3 months, and without MTOR mutations in 13 cases, the median overall survival time for 42.6 months (P=0.71), with APC mutations in 2 cases, the median overall survival time for 39.0 months, and without APC mutations in 13 cases, the median overall survival time for 42.6 months (P=0.92).Conclusion: There is some significant difference of clinical features in HER2 gene mutations with non-smoking women in non-small cell lung cancer, along with the state of HER2 gene mutations little influence on prognosis.关键词
非小细胞肺癌/HER2/临床特征/预后Key words
non-small cell lung cancer/HER2/clinical features/prognosis引用本文复制引用
黄章洲,王文娴,庄武,黄韵坚,许春伟,方美玉,朱有才,杜开齐,陈刚..非小细胞肺癌患者中HER2基因突变的临床特征及预后[J].临床与病理杂志,2017,37(9):1855-1860,6.基金项目
国家临床重点专科建设项目(2013) （2013）
福建省科技厅引导性项目(2016Y0019,2015Y0011) （2016Y0019,2015Y0011）
浙江省卫生科研计划基金(2013KYB051) （2013KYB051）
浙江省中医药局科研基金(2013ZQ005) （2013ZQ005）
浙江省科技厅公益类科研计划(2015C33194) （2015C33194）
吴阶平医学基金会临床科研资金项目(20114272111) （20114272111）
嘉兴市科技计划项目(2016AY23087).This work was supported by National Clinical Key Specialty Construction Program(2013) （2016AY23087）
Leading Project Foundation of Science Department of Fujian Province(2016Y0019, 2015Y0011) （2016Y0019, 2015Y0011）
Medical Scientific Research Foundation of Zhejiang Province(2013KYB051) （2013KYB051）
Zhejiang Administration of Traditional Chinese Medicine Foundation(2013ZQ005) （2013ZQ005）
The Science and Technology Planning Project of Zhejiang Province(2015C33194) （2015C33194）
Wu Jieping Medical Foundation Clinical Scientific Research Project Funds(20114272111) （20114272111）
Science and Technology Plan Projects of Jiaxing of Zhejiang(2016AY23087), China. （2016AY23087）
